caa a22 4500 469121610 CHVBK 20180323133140.0 cr unu---uuuuu 170328e19920201xx s 000 0 eng 10.1007/BF02246235 doi (NATIONALLICENCE)springer-10.1007/BF02246235 Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations [Elektronische Daten] [J. Dingemanse, A. Korn, J. Pfefen, T. Güntert] The effects of high single doses of moclobemide (300, 450 and 600 mg given at the end of a standardized meal) on plasma levels of several catecholamines and their deaminated metabolites, and on plasma levels of pituitary hormones were determined in eight healthy young male volunteers in a randomised, double-blind, placebo-controlled study. Assessment of the i.v. tyramine potentiation and determination of the plasma levels of moclobemide were also performed. The tyramine sensitivity factor at 2 h after dosing was about 2.1, with no significant differences between the doses used. The inhibitory activity of moclobemide on MAO-A was reflected in significant reductions of plasma concentrations of DHPG and 5-HIAA. No clear differences were detected between the moclobemide doses. Prolactin plasma concentrations were only slightly increased after the two higher doses. The plasma concentrations of moclobemide were very much in agreement with those found in previous studies under similar experimental conditions. Thus, single oral doses of 300, 450 and 600 mg moclobemide demonstrated marked inhibition of MAO-A activity, whereas a single dose of 300 mg induced a near-maximum effect. Springer-Verlag, 1992 Moclobemide nationallicence Catecholamines nationallicence Concentration-effect relationship nationallicence Dingemanse J. Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut Korn A. Division of Clinical Pharmacology, University Hospital, A-1090, Vienna, Austria aut Pfefen J. Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut Güntert T. Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut Psychopharmacology Springer-Verlag 106(1992-02-01), S46-S48 0033-3158 106<S46 1992 106 213 https://doi.org/10.1007/BF02246235 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02246235 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Dingemanse J. Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut NATIONALLICENCE 700 1- Korn A. Division of Clinical Pharmacology, University Hospital, A-1090, Vienna, Austria aut NATIONALLICENCE 700 1- Pfefen J. Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut NATIONALLICENCE 700 1- Güntert T. Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 106(1992-02-01), S46-S48 0033-3158 106<S46 1992 106 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer